No 10Y consistency score yet for revenue — the window needs more comparable quarters.
Valuation vs own 10Y history: P/S 3.3x · 10Y median 2.8x · 70th percentile · as of Oct 6, 2026
Annualized revenue (TTM) · by quarter, last 16
Quarterly YoY revenue growth vs the 20% line
P/S multiple vs its 10Y median
FMP quote market capitalization / revenue from four consecutive issuer fiscal quarters. Quote observation: 2026-10-06T14:32:20.721Z. Latest historical point 2026-10-05. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
Current FMP quote-based enterprise value / four-quarter operating income plus matched D&A. Quote observation: 2026-10-06T14:32:20.721Z. Latest historical point 2026-10-05. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
FMP quote market capitalization / four-quarter operating cash flow. Quote observation: 2026-10-06T14:32:20.721Z. Latest historical point 2026-02-26. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
FMP quote market capitalization / four-quarter operating cash flow less absolute capital expenditures. Quote observation: 2026-10-06T14:32:20.721Z. Latest historical point 2026-02-26. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
Unrounded diluted TTM EPS / FMP quote price × 100. Quote observation: 2026-10-06T14:32:20.721Z. Latest historical point 2026-10-05.
Four-quarter operating EBITDA / current FMP quote-based enterprise value × 100. Quote observation: 2026-10-06T14:32:20.721Z. Latest historical point 2026-10-05. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
Four-quarter operating cash flow / FMP quote market capitalization × 100. Quote observation: 2026-10-06T14:32:20.721Z. Latest historical point 2026-02-26. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
Four-quarter free cash flow / FMP quote market capitalization × 100. Quote observation: 2026-10-06T14:32:20.721Z. Latest historical point 2026-02-26. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
The latest delayed quote for Indivior Pharmaceuticals Inc (INDV) stock was $35.08 as of Oct 6, 2026, 10:30 AM EDT, down 2.54% from the previous close.
Longer view (total return, dividends reinvested): past 12 months +55.0% · 3-year avg +21.0%/yr · 5-year avg +19.6%/yr
Indivior Pharmaceuticals Inc. operates as a holding company, primarily engaged in the research, production, and distribution of buprenorphine-based prescription medications designed to treat opioid dependence.
Drug Manufacturers - Specialty & Generic · North Chesterfield, VA
Selected amounts supplied by FMP for each displayed period. Reviewed label references appear where available; other labels are unverified, and items may overlap.
2025-12-31 · USD
Reviewed labels link to their filing; other labels are unverified FMP source labels.
Reviewed presentation labels and parent/child details link to filing evidence; other FMP source labels remain unverified. Mutual exclusivity and reconciliation to a total for the same reporting period and currency have not been verified; percentages and stacked totals are unavailable.
2024-12-31 · USD
Reviewed labels link to their filing; other labels are unverified FMP source labels.
Reviewed presentation labels and parent/child details link to filing evidence; other FMP source labels remain unverified. Mutual exclusivity and reconciliation to a total for the same reporting period and currency have not been verified; percentages and stacked totals are unavailable.
Next Earnings Date
Oct 29, 2026
23 days away
EPS Estimate
1.06
Revenue Est.
$329.35M
Last Quarter Results
EPS
$1.15
vs Estimate
$0.92
Revenue
| Stock | Market Cap | Close Price | Price Change | TTM Total Return | 5Y CAGR | 10Y CAGR | Compare |
|---|---|---|---|---|---|---|---|
| 1INDV | $4.38B | $35.08 | -2.54% | +55.00% | +19.65% | +6.16% | N/A |
| 2HTFL | $4.40B | $50.99 | -2.33% | +38.49% | N/A | N/A | vs INDV |
| 3EWTX | $4.28B | $39.79 | -1.27% | +156.35% | +16.95% | N/A | vs INDV |
| 4ADPT | $4.51B | $28.20 | -5.50% | +106.79% | -1.77% | N/A | vs INDV |
| 5LIVN | $4.13B | $75.16 | -1.66% | +42.96% | -1.66% | +2.48% | vs INDV |
| 6LFST | $4.63B | $11.95 | -2.21% | +120.94% | -1.46% | N/A | vs INDV |
TTM
3.29
$343.00M
vs Estimate
$306.23M
Consensus Rating
Based on 4 analysts
Average Price Target
$49.00
+39.7% upside
Low
$43.00
Current
$35.08
High
$53.00
Quarterly
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| Quarter ending Sep 2026 | $1.04 | $1.06 | $1.07 | 1 |
| Quarter ending Dec 2026 | $1.15 | $1.17 | $1.18 | 1 |
| Quarter ending Mar 2027 | $1.06 | $1.08 | $1.09 | 1 |
| Quarter ending Jun 2027 | $1.21 | $1.22 | $1.24 | 1 |
Annual
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| FY 2026 | $4.18 | $4.22 | $4.25 | 2 |
| FY 2027 | $4.58 | $4.62 | $4.65 | 2 |
Quarterly
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| Quarter ending Sep 2026 | $326.20M | $329.35M | $332.50M | 1 |
| Quarter ending Dec 2026 | $334.67M | $337.90M | $341.13M | 1 |
| Quarter ending Mar 2027 | $324.86M | $328.00M | $331.14M | 1 |
| Quarter ending Jun 2027 | $345.86M | $349.20M | $352.54M | 1 |
Annual
| Period |
|---|
Source: FMP Analyst Consensus Estimates. Forward P/E uses the consensus EPS estimate for the fiscal year ending Dec 31, 2026, matching Key Metrics.
| Low |
|---|
| Avg |
|---|
| High |
|---|
| # Analysts |
|---|
| FY 2026 | $1.32B | $1.33B | $1.34B | 3 |
| FY 2027 | $1.39B | $1.40B | $1.41B | 3 |
